Legumain promotes fibrogenesis in chronic pancreatitis via activation of transforming growth factor β1

• Published in: Journal of molecular medicine (Berlin, Germany) Vol. 98; no. 6; pp. 863 - 874
• Main Authors: Ren, Ying-Chun, Zhao, Qiuyan, He, Yan, Li, Bin, Wu, Zengkai, Dai, Juanjuan, Wen, Li, Wang, Xingpeng, Hu, Guoyong
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.06.2020; Springer Nature B.V
• Subjects: Biomedical and Life Sciences; Biomedicine; Cell activation; Enzyme-linked immunosorbent assay; Extracellular matrix; Fibrosis; Gelatin; Gelatinase A; Growth factors; Histology; Human Genetics; Immunofluorescence; Inflammatory diseases; Internal Medicine; Legumain; Macrophages; Matrix metalloproteinase; Metalloproteinase; Molecular Medicine; Original Article; Pancreatic cancer; Pancreatitis; Polymerase chain reaction; Reverse transcription; Risk factors; Stellate cells; Therapeutic applications; Transforming growth factor-b1; Western blotting; Pancreatic fibrosis; Pancreatic stellate cells; TGF-β1; Legumain; Chronic pancreatitis
• ISSN: 0946-2716; 1432-1440
• DOI: 10.1007/s00109-020-01911-0

Chronic pancreatitis (CP) is a major risk factor for pancreatic cancer; however, little is known about the pathogenic mechanisms underlying the development of CP. Legumain (Lgmn) has been linked to some chronic inflammatory diseases. The present study investigated the role of legumain in pancreatic fibrogenesis. We induced CP in wild type C57BL6 (WT), Lgmn-deficient (Lgmn −/− ), Lgmn flox/flox and Lgmn flox/flox × LysM Cre mice by intraperitoneal injection of caerulein for 4 weeks. Pancreata were collected and analyzed by quantitative reverse transcription polymerase chain reaction, Western blotting, and histology. Pancreatic stellate cells and macrophages were isolated and studied using immunofluorescence, gelatin zymography, and enzyme-linked immunosorbent assay. The effects of inhibition of legumain were investigated in vivo by administration of the specific legumain inhibitor, RR-11a. Legumain was found to be upregulated in the serum and pancreatic tissues of mice with caerulein-induced CP. Mice with global and macrophage-specific legumain deficiency exhibited significantly reduced development of pancreatic fibrosis compared with control mice, based on pancreas size, histology, and expression of fibrosis-associated genes. Our results indicate that legumain promotes activation of pancreatic stellate cells and increases synthesis of extracellular matrix proteins via activation of matrix metalloproteinase-2(MMP-2), which hydrolyzes the transforming growth factor-β1 (TGF-β1) precursor to form active TGF-β1. Administration of RR-11a markedly attenuated pancreatic fibrosis in mice with CP. Deficiency or inhibition of legumain significantly reduces the severity of pancreatic fibrosis by suppressing activation of the TGF-β1 precursor. Our results highlight the potential of legumain as a novel therapeutic target for CP. Key messages • Legumain expression was markedly upregulated in CP mice. • Deletion of legumain attenuated pancreatic fibrosis in CP mice. • Legumain promotes fibrosis via MMP-2 activation, which hydrolyzed the TGF-β1 precursor to the active form. • Legumain is a potential therapeutic target for the management of CP.